Datapoint: U.S. Supreme Court Lifts Gilenya Generics Block

October 18

The United States Supreme Court last week lifted an order that blocks generic copies of Novartis’ multiple sclerosis (MS) drug Gilenya from hitting the market. The court is still considering whether to hear the drugmaker’s patent dispute against HEC Pharm. Gilenya is a blockbuster, and Novartis’ No. 3 bestselling drug, according to data from Evaluate Pharma. For the treatment of MS, Gilenya holds covered or better status for virtually all (99%) of insured lives under the pharmacy benefit. 11.5% of covered lives have preferred access to Gilenya, growing to 47% with utilization management restrictions applied.

SOURCE: MMIT Analytics and Evaluate Pharma, as of 10/17/22